Recursion Pharmaceuticals, Inc. (RXRX)
4.16
+0.42
(+11.23%)
USD |
NASDAQ |
Oct 15, 16:00
4.17
+0.01
(+0.24%)
After-Hours: 05:10
Recursion Pharmaceuticals Cash from Operations (TTM) : -350.48M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -350.48M |
| March 31, 2026 | -320.95M |
| December 31, 2025 | -371.81M |
| September 30, 2025 | -441.16M |
| June 30, 2025 | -383.03M |
| March 31, 2025 | -388.83M |
| December 31, 2024 | -359.17M |
| September 30, 2024 | -317.82M |
| June 30, 2024 | -331.52M |
| March 31, 2024 | -316.76M |
| December 31, 2023 | -287.78M |
| September 30, 2023 | -258.45M |
| Date | Value |
|---|---|
| June 30, 2023 | -240.07M |
| March 31, 2023 | -234.23M |
| December 31, 2022 | -83.52M |
| September 30, 2022 | -99.93M |
| June 30, 2022 | -78.44M |
| March 31, 2022 | -50.47M |
| December 31, 2021 | -158.61M |
| September 30, 2021 | -88.88M |
| June 30, 2021 | -75.29M |
| March 31, 2021 | -58.34M |
| December 31, 2020 | -45.40M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Absci Corp. | -108.08M |
| Twist Bioscience Corp. | -53.07M |
| Editas Medicine, Inc. | -119.86M |
| Amgen, Inc. | 12.48B |
| Halozyme Therapeutics, Inc. | 818.60M |